Compare Charles River Laboratories Intl. Inc (CRL) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Vanguard High Dividend Yield ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $302.66 (market cap $14.23B), while Vanguard High Dividend Yield ETF trades at $158.69 (market cap $100.80B). The key difference: Vanguard High Dividend Yield ETF is far larger — about 7.1× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Vanguard High Dividend Yield ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Vanguard High Dividend Yield ETF for 138 Days on average.
| CRL | VYM | |
|---|---|---|
Market Cap | $14.23B | $100.80B |
Volume | 1,176,885 | 908,176 |
Sector | Health | — |
52-Week High | $310.77 | $167.03 |
52-Week Low | $149.93 | $137.47 |
Typical Hold Time | 33 Days | 138 Days |
Enterprise Value | $17.06B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
VYM trades at $158.56, up 0.7% with a bearish technical signal from moving averages. The ETF faces mixed sentiment as articles highlight its consistent dividend yield of 2.42% but note underperformance versus peers like SCHD and IDV. Support sits at $156, with resistance at $159-160. Recent news questions its stock selection methodology after holding Intel and Walgreens through dividend cuts.
Outlook remains cautious due to technical bearishness and competitive pressure from higher-yielding alternatives. Risks include sector concentration in dividend-cut-prone stocks and inflation persistence. Opportunities lie in its low expense ratio and broad diversification across nearly 600 holdings for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
